NASDAQ$APGE
Apogee Therapeutics Inc · Q2 2026 earnings
Q2 2026 earnings · · Before market open · Investor relations
Briefing
Apogee Therapeutics Inc reported its financial results for the second quarter ended June 30, 2026.
Apogee Therapeutics Inc, a clinical-stage biotechnology company, reported a net loss of $85.9 million for the three months ended June 30, 2026, compared to $66.1 million in the prior year period. The company continued advancing its pipeline of antibody programs targeting inflammatory and immunology indications, with increased research and development expenses driven by clinical trial activities for zumilokibart and other candidates. Cash and cash equivalents stood at $105.6 million, supported by recent equity offerings and a revenue share agreement.
- Net loss for Q2 2026 was $85.9 million with basic and diluted EPS of $(1.14).
- Research and development expenses increased to $67.3 million from $55.7 million year-over-year due to pipeline advancement.
- General and administrative expenses rose to $24.3 million, reflecting growth in operations and merger-related costs.
- The company entered into a merger agreement with AbbVie and a $100 million revenue share financing with Blackstone Life Sciences.
Headline financials
Revenue & EPS history
Apogee · Revenue · Quarterly
$0
Forward guidance
The company plans to initiate Phase 3 trials for zumilokibart in AD in the second half of 2026 with data readouts expected in 2027 and 2028.
Tailwinds
- Positive 52-week maintenance data from APEX Part A trial supporting three- and six-month dosing.
- Initiation of Phase 1b trial for APG279 with data readout anticipated in second half of 2026.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports
+5.6%
Avg return
Earnings day
+9.2%
Avg return
5 days after
+10.9%
Avg return
30 days after
53%
8 / 15 earnings
Positive
+59.8%
Q4 2023
Best reaction
-12.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q4 2025 | +1.2% | +4.4% | +20.3% | |
| Q3 2025 | +3.8% | +19.7% | +39.0% | |
| Q2 2025 | -2.2% | +5.4% | +5.9% | |
| Q1 2025 | -0.0% | -1.1% | +9.4% | |
| Q4 2024 | -0.2% | +14.9% | +20.3% | |
| Q3 2024 | -12.7% | -21.8% | -26.7% | |
| Q2 2024 | +9.7% | +11.7% | +25.0% | |
| Q1 2024 | +1.5% | -5.5% | -16.7% | |
| Q1 2023 | +1.5% | -5.5% | -16.7% | |
| Q4 2023 | +59.8% | +61.8% | +41.4% | |
| Q3 2023 | +12.8% | +20.6% | +45.9% | |
| Q3 2022 | +12.8% | +20.6% | +45.9% | |
| Q2 2023 | -1.1% | +4.0% | -9.6% | |
| Q4 2022 | -1.1% | +4.0% | -9.6% | |
| Q2 2022 | -1.1% | +4.0% | -9.6% | |
| Q1 2022 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro